PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde
Ipsen’s grand plan to open up new markets for the cancer drug Onivyde has hit a snag. Its Phase III trial testing the therapy in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
